Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NCT01499121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell, Metastatic Renal Cell Carcinoma

Interventions

DRUG: Sunitinib

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]